


Listing of Claims:


Claim 1 (currently amended) A compound selected from the group consisting of all possible isomeric forms and their mixtures of a compound of the formula




wherein either R_1 and R_2 are individually selected from the group consisting of hydrogen, hydroxyl, alkyl and cycloalkyl of up to 8 carbon atoms optionally interrupted by oxygen and optionally substituted by a member selected from the group consisting of




are individually hydrogen or alkyl of 1 to 8 carbon atoms ~~or a and b can optionally form with the nitrogen atom a heterocycle optionally containing at least one additional heteroatom~~, or R_1 forms with the endocyclic carbon atom carrying



the group consisting of oxygen, -NH- or -N-alkyl of 1 to 8 carbon atoms and Ra is selected from the group consisting of hydrogen, alkyl or cycloalkyl of up to 8 carbon atoms substituted by at least one member of the group consisting of halogen, -OH, -CO₂H, -CO₂alk, and



a' and b' are hydrogen or alkyl of 1 to 8 carbon atoms ~~or a' and b' can form a heterocycle optionally containing at least one additional heteroatom or~~ and heterocycle containing at least one heteroatom or R₂ is










in which d, e, f and g are hydrogen or alkyl of 1 to 8 carbon atoms, f and g can also be acyl of up to 8 carbon atoms, ~~and e and f can also form a ring optionally containing at least one heteroatom,~~

R₃ is selected from the group consisting of hydrogen, methyl and hydroxyl,



R₄ is hydrogen or hydroxyl,

R is selected from the group consisting of


R is selected from the group consisting of



and



and



T is selected from the group consisting of hydrogen, methyl, $-\text{CH}_2\text{CONH}_2$, $-\text{CH}_2\text{CN}$, $-(\text{CH}_2)_2\text{NH}_2$ and $-(\text{CH}_2)\text{Nalk}^+\text{X}^-$, X is halogen and alk is alkyl of up to 8 carbon atoms, Y is selected from the group consisting of hydrogen, hydroxyl, halogen and OSO_3H and a salt thereof, W is hydrogen or $-\text{OH}$, Z is hydrogen or methyl and a non-toxic, pharmaceutically acceptable acid addition salt thereof.

Claim 2 (previously presented) A compound of claim 1 in which T is hydrogen.

Claim 3 (previously presented) A compound of claim 1 in which W is hydrogen.

Claim 4 (previously presented) A compound of claim 1 in which Z is methyl.




Claim 5 (previously presented) A compound of claim 1 in which Y is hydrogen.

Claim 6 (previously presented) A compound of claim 1 in which R₃ is methyl.



Claim 7 (previously presented) A compound of claim 1 in which R₄ is hydroxyl.

Claim 8 (currently amended) A compound of claim 1 in which R is selected from the group

consisting of




and




Claim 9 (previously presented) A compound of claim 1 in which R₁ is hydrogen.


Claim 10 (previously presented) A compound of claim 1 in which R₂ is



Claim 11 (previously presented) A compound of claim 1 in which R₂ is



Claim 12 (previously presented) A compound of claim 1 in which R₂ is selected from the group consisting of




Claim 13 (previously presented) A compound of claim 1 selected from the group consisting of


- 1-[4-[(2-aminoethyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-3-isoxazolyl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- trans-1-[4-[(2-aminocyclohexyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-3-isoxazolyl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- 1-[4-[(2(S)-aminopropyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-3-isoxazolyl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- 1-[4-[(2-aminoethyl)amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-1,3,4-thiadiazol-2-yl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate,
- trans 1-[4-[(2-aminocyclohexyl)-amino]-N2-[[4-[5-[4-(pentyloxy)-phenyl]-1,3,4-thiadiazol-2-yl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate and
- trans 1-[4-[(2-aminocyclohexyl)-amino]-N2-[[4-[3-[4-(pentyloxy)-phenyl]-1,2,4-oxadiazol-5-yl]-phenyl]-carbonyl]-L-ornithine]-4-[4-(4-hydroxyphenyl)-L-threonine]-5-L-serine-echinocandine B trifluoroacetate.

Claim 14 (previously presented) A process for the preparation of a compound of claim 1

reacting a compound of the formula




in which R, R₃, R₄, T, Y, W and Z are defined as in claim 1 with an amine or of an amine derivative capable of introducing




and optionally then with a reducing agent,
and/or a functionalization agent of the amine,
and/or an acid to form the salt of the product of claim 1,
and/or a separation agent of the different isomers obtained.

Claim 15 (previously presented) A compound of the formula




wherein R, R₃, R₄, T, Y, W and Z are defined as in claim 1.


Claim 16 (previously presented) A process of claim 14 wherein a compound of the formula



R₃, R₄, T, W, Y and Z are defined as in claim 14 reacted with an agent capable of replacing -NH₂ by -NHR, R being defined as in claim 14 to obtain a compound of the formula




reacting the said compound with trimethylsilyl iodide to obtain the corresponding compound of the formula




Claims 17-19 (cancelled)

Claim 20 (previously presented) A compound of claim 11 wherein R₂ is




Claim 21 (previously presented) A compound of the formula



(III)

~~or~~



(IV)

wherein R, R₃, R₄, T, W, Y and Z are defined as in claim 1.

Claim 22 (currently amended) An antifungal composition comprising an antifungally effective amount of a compound of claim 1 and ~~in~~ an inert pharmaceutical carrier.

Claim 23 (previously presented) A method of treating fungal infections in warm-blooded animals comprising administering to warm-blooded animals in need thereof an antifungally effective amount of a compound of claim 1.